Last 7 days
-5.1%
Last 30 days
-2.2%
Last 90 days
115.8%
Trailing 12 Months
242.9%
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
Revenue | NaN% | null | null | 40,000,000 | 30,069,000 | 20,138,000 |
Gross Profit | - | 160,000,000 | - | - | - | - |
Operating Expenses | -7.0% | 107,482,000 | 115,522,000 | 113,313,000 | 112,547,000 | - |
S&GA Expenses | -7.7% | 29,606,000 | 32,065,000 | 33,907,000 | 39,604,000 | - |
R&D Expenses | -6.7% | 77,876,000 | 83,457,000 | 79,406,000 | 72,943,000 | - |
EBITDA | 7.5% | -53,778,000.00 | -58,153,000.00 | -54,618,000.00 | - | - |
EBITDA Margin | 7.5% | -1.34 | -1.45 | - | - | - |
Earnings Before Taxes | 7.4% | -54,776,000.00 | -59,132,000.00 | -55,587,000.00 | -56,864,000.00 | - |
EBT Margin | 7.4% | -1.37 | -1.48 | - | - | - |
Interest Expenses | 1.8% | 346,000 | 340,000 | 340,000 | 290,000 | - |
Net Income | 7.3% | -54,814,000.00 | -59,116,000.00 | -55,569,000.00 | -57,132,000.00 | - |
Net Income Margin | 7.3% | -1.37 | -1.48 | - | - | - |
Free Cahsflow | 2.3% | -28,551,000.00 | -29,227,000.00 | -33,266,000.00 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | 77.5% | 275 | 155 | 169 | 187 | 202 |
Current Assets | 86.4% | 258 | 139 | 153 | 170 | 184 |
Cash Equivalents | 107.8% | 232 | 112 | 133 | 148 | 167 |
Net PPE | -11.0% | 0 | 0 | 0 | 0 | 0 |
Goodwill | -0.2% | 1 | 1 | 1 | 1 | 1 |
Liabilities | -15.0% | 37 | 44 | 43 | 39 | 33 |
Current Liabilities | -17.3% | 32 | 39 | 38 | 33 | 28 |
LT Debt, Non Current | 1.1% | 5 | 5 | 5 | 5 | 5 |
Shareholder's Equity | 114.2% | 237 | 111 | 126 | 148 | 168 |
Retained Earnings | -5.1% | -322.44 | -306.65 | -288.74 | -263.72 | -240.29 |
Additional Paid-In Capital | 34.6% | 526 | 391 | 388 | 385 | 382 |
Shares Outstanding | 24.1% | 602 | 485 | 483 | 480 | 478 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -143.4% | -69,447.00 | -28,527.00 | -29,215.00 | -33,254.00 | -34,726.00 |
Share Based Compensation | -13.3% | 13,804 | 15,926 | 20,323 | 25,425 | 34,112 |
Cashflow From Investing | 26.8% | -30.00 | -41.00 | -12.00 | -12.00 | -20.00 |
Cashflow From Financing | 3422.1% | 137,303 | -4,133.00 | -6,843.00 | -6,117.00 | -1,266.00 |
100%
100%
87.7%
Y-axis is the maximum loss one would have experienced if Verona Pharma was unfortunately bought at previous high price.
12.1%
52.4%
FIve years rolling returns for Verona Pharma.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-01-19 | Stratos Wealth Partners, LTD. | new | - | 479,747 | 479,747 | 0.01% |
2023-01-13 | JANUS HENDERSON GROUP PLC | new | - | 6,138,000 | 6,138,000 | -% |
2022-11-16 | GLENMEDE TRUST CO NA | new | - | 308,000 | 308,000 | -% |
2022-11-15 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
2022-11-15 | STATE STREET CORP | new | - | 4,234,000 | 4,234,000 | -% |
2022-11-14 | Octagon Capital Advisors LP | new | - | 13,540,000 | 13,540,000 | 2.34% |
2022-11-14 | TWO SIGMA ADVISERS, LP | new | - | 1,568,000 | 1,568,000 | -% |
2022-11-14 | BREWIN DOLPHIN LTD | unchanged | - | -1,000 | 3,000 | -% |
2022-11-14 | SPHERA FUNDS MANAGEMENT LTD. | new | - | 1,226,000 | 1,226,000 | 0.17% |
2022-11-14 | NEA Management Company, LLC | added | 9.32 | 35,671,000 | 57,076,000 | 2.85% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Dec 27, 2022 | orbimed advisors llc | 5.6% | 4,260,691 | SC 13D/A | |
Sep 07, 2022 | growth equity opportunities fund iv, llc | 7.9% | 46,447,651 | SC 13D/A | |
Feb 14, 2022 | ra capital management, l.p. | 9.99% | 48,778,172 | SC 13G/A | |
Feb 11, 2022 | vivo ventures vi, llc | 0% | 0 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 8.34% | 38,655,904 | SC 13G | |
Feb 16, 2021 | ra capital management, l.p. | 9.99% | 41,543,004 | SC 13G | |
Feb 05, 2021 | novo holdings a/s | 3.1% | 12,893,250 | SC 13G/A | |
Oct 05, 2020 | novo holdings a/s | 5.4% | 22,639,667 | SC 13D/A | |
Aug 03, 2020 | growth equity opportunities fund iv, llc | 10.2% | 42,638,131 | SC 13D/A | |
Jul 31, 2020 | abingworth llp | 5.1% | 21,064,222 | SC 13D/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Dec 27, 2022 | 4 | Insider Trading | |
Dec 27, 2022 | 4 | Insider Trading | |
Dec 27, 2022 | 4 | Insider Trading | |
Dec 27, 2022 | SC 13D/A | 13D - Major Acquisition | |
Dec 21, 2022 | 4 | Insider Trading | |
Dec 21, 2022 | 4 | Insider Trading | |
Dec 20, 2022 | 8-K | Current Report | |
Nov 15, 2022 | S-8 | Employee Benefits Plan | |
Nov 09, 2022 | 10-Q | Quarterly Report | |
Nov 09, 2022 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-12-23 | ORBIMED ADVISORS LLC | sold | -49,576,600 | 22.8425 | -2,170,370 | - |
2022-12-23 | Gupta Rishi | sold | -49,576,600 | 22.8425 | -2,170,370 | - |
2022-12-22 | Poll Claire | sold | -646,032 | 2.6918 | -240,000 | general counsel |
2022-12-22 | ORBIMED ADVISORS LLC | sold | -86,424,200 | 21.7721 | -3,969,500 | - |
2022-12-22 | Gupta Rishi | sold | -86,424,200 | 21.7721 | -3,969,500 | - |
2022-12-20 | Hahn Mark W | sold | -1,269,060 | 2.1151 | -600,000 | chief financial officer |
2022-12-20 | ZACCARDELLI DAVID | sold | -1,269,600 | 2.116 | -600,000 | president and ceo |
2022-11-22 | Poll Claire | gifted | - | - | 170,000 | general counsel |
2022-11-22 | Poll Claire | gifted | - | - | -170,000 | general counsel |
2022-11-01 | Hahn Mark W | sold | -22,011.4 | 1.6726 | -13,160 | chief financial officer |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Statement [Abstract] | ||||
Revenue | $ 0 | $ 40,000 | $ 0 | $ 40,000 |
Gross profit | 0 | 40,000 | 0 | 40,000 |
Operating expenses | ||||
Research and development | 9,838 | 22,560 | 42,445 | 56,697 |
Selling, general and administrative | 5,290 | 10,883 | 18,256 | 28,150 |
Total operating expenses | 15,128 | 33,443 | 60,701 | 84,847 |
Operating (loss)/profit | (15,128) | 6,557 | (60,701) | (44,847) |
Other (expense)/income | ||||
Research and development tax credit | 2,127 | 4,749 | 8,838 | 10,655 |
Interest income | 779 | 4 | 959 | 11 |
Interest expense | (116) | (86) | (291) | (255) |
Fair value movement on warrants | 0 | 40 | 0 | 2,244 |
Foreign exchange (loss)/gain | (3,245) | (86) | (6,830) | 117 |
Total other (expense)/income, net | (455) | 4,621 | 2,676 | 12,772 |
(Loss)/profit before income taxes | (15,583) | 11,178 | (58,025) | (32,075) |
Income tax expense | (64) | (127) | (225) | (232) |
Net (loss)/profit | $ (15,647) | $ 11,051 | $ (58,250) | $ (32,307) |
Profit/(loss) per share, basic (in dollars per share) | $ (0.03) | $ 0.02 | $ (0.12) | $ (0.07) |
Profit/(loss) per share, diluted (in dollars per share) | $ (0.03) | $ 0.02 | $ (0.12) | $ (0.07) |
Weighted-average shares outstanding, basic (in shares) | 544,134,136 | 475,334,354 | 503,751,844 | 471,159,171 |
Weighted-average shares outstanding, diluted (in shares) | 544,134,136 | 515,819,439 | 503,751,844 | 471,159,171 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 231,701 | $ 148,380 |
Prepaid expenses | 3,355 | 4,037 |
Tax and tax incentive receivable | 20,321 | 15,583 |
Other current assets | 3,077 | 2,063 |
Total current assets | 258,454 | 170,063 |
Non-current assets: | ||
Furniture and equipment, net | 81 | 80 |
Goodwill | 544 | 545 |
Equity interest | 15,000 | 15,000 |
Right-of-use assets | 793 | 899 |
Total non-current assets | 16,418 | 16,524 |
Total assets | 274,872 | 186,587 |
Current liabilities: | ||
Accounts payable | 8,002 | 10,044 |
Accrued expenses | 22,978 | 22,256 |
Operating lease liability | 569 | 648 |
Taxes payable | 285 | 147 |
Other current liabilities | 294 | 327 |
Total current liabilities | 32,128 | 33,422 |
Non-current liabilities: | ||
Term loan | 5,035 | 4,874 |
Operating lease liability | 224 | 286 |
Total non-current liabilities | 5,259 | 5,160 |
Total liabilities | 37,387 | 38,582 |
Commitments and contingencies | ||
Shareholders' equity: | ||
Ordinary £0.05 par value shares; 608,138,246 and 489,177,550 issued, and 602,215,606 and 480,082,966 outstanding, at September 30, 2022 and December 31, 2021, respectively | 39,119 | 31,855 |
Additional paid-in capital | 525,858 | 385,070 |
Ordinary shares held in treasury | (449) | (603) |
Accumulated other comprehensive loss | (4,601) | (4,601) |
Accumulated deficit | (322,442) | (263,716) |
Total shareholders' equity | 237,485 | 148,005 |
Total liabilities and shareholders' equity | $ 274,872 | $ 186,587 |